首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1738576

全球吸入抗生素市場規模（按產品類型、應用、分銷管道、區域範圍和預測）

Global Inhaled Antibiotics Market Size By Product Type (Aerosol/Metered Dose Inhaler, Dry Powder Formulation), By Application (Pneumonia, Asthma), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Geographic Scope And Forecast

出版日期: 2025年05月12日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

吸入抗生素的市場規模和預測

2024 年吸入式抗生素市場規模為 12.8 億美元，預計到 2032 年將達到 20.6 億美元，預測期內（2026-2032 年）的複合年成長率為 6.17%。

近年來，由於氣喘、慢性阻塞性肺病(COPD)、支氣管炎和新冠肺炎 (COVID-19) 等慢性呼吸系統疾病的發生率不斷上升，全球吸入式抗生素市場發展勢頭強勁。此外，不斷增加的研發投入和企業動機是吸入式抗生素的成長要素，預示著預測期內吸入式抗生素市場將擁有巨大的成長機會。全球吸入式抗生素市場報告對市場進行了全面評估，全面分析了關鍵細分市場、趨勢、市場促進因素、限制因素、競爭格局以及影響市場的關鍵因素。

定義全球吸入抗生素市場

吸入式抗生素包括妥布黴素和粘菌素的霧化和乾粉劑，以及霧化Aztreonam。吸入式抗生素主要用於治療呼吸道感染疾病。引起支氣管擴張的慢性呼吸道疾病伴隨難以治療的感染疾病，是治療上的一大挑戰。患有囊性囊腫纖維化(CF) 和非 CF 支氣管擴張等慢性呼吸道疾病的患者容易受到銅綠假單胞菌、抗藥性金黃色葡萄球菌、鼠傷寒伯克霍爾德菌和非結核分枝桿菌的混合感染疾病的折磨。

吸入式抗生素的優點在於，它能夠將高濃度的藥物輸送至感染疾病部位，而不會產生腸外或口服抗生素治療常見的全身性副作用。近幾十年來，人們對開發吸入式抗生素以幫助控制感染疾病（尤其是感染疾病難以根除或復發率高的感染）的興趣日益濃厚。與全身性療法相比，吸入式抗生素在治療下呼吸道感染疾病方面具有顯著優勢。

全球吸入抗生素市場概況

慢性呼吸道感染疾病可透過吸入式抗生素治療。這些吸入式抗生素被認為比其他途徑更有效，因為它們能在標靶輸送更高的藥物濃度，這很可能促進吸入式抗生素市場的成長。氣喘、肺炎、慢性阻塞性肺病(COPD) 和支氣管炎等呼吸系統疾病的盛行率不斷上升，預計將推動整個吸入式抗生素市場的成長。氣喘也是影響全球數百萬人的主要公共衛生問題。

慢性阻塞性肺病(COPD) 是另一種危及生命的肺部疾病，會導致過早死亡和高死亡率。慢性支氣管炎和肺氣腫都是慢性阻塞性肺病的症狀。此外，新產品研發活動的活性化也有望推動吸入式抗生素市場的成長。吸入式抗生素長期以來一直用於治療囊腫纖維化患者的肺部感染疾病，並且也正在研究其用於治療其他肺部感染疾病途徑，尤其是針對多重抗藥性和廣泛抗藥性的患者，例如結核病。

另一方面，吸入藥物的副作用以及難以開發出一種能夠治療多種疾病的有效吸入裝置，可能會阻礙吸入抗生素市場的成長。此外，由於運輸設施不規範，抗生素生產所需的原料藥（API）等原料供應不足，預計將影響吸入抗生素市場的全球分銷管道。

Global Inhaled Antibiotics Market has gained momentum in recent times because of the increasing incidence of chronic respiratory disorders such as asthma, chronic obstructive pulmonary diseases (COPD), bronchitis, and COVID-19. Furthermore, an increase in research and development and company initiatives are the factors for the growth of the inhaled antibiotics which shows significant opportunities for Inhaled Antibiotics Market growth over the forecast period. The Global Inhaled Antibiotics Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Inhaled Antibiotics Market Definition

Inhaled antibiotics include nebulized and dry powder versions of tobramycin and colistin, as well as nebulized aztreonam. Inhaled antibiotics are primarily used to treat infections of the respiratory tract. Chronic respiratory disorders that cause bronchiectasis are associated with difficult-to-treat infections, posing a significant therapeutic challenge. Complex infections caused by Pseudomonas aeruginosa, Methicillin-resistant Staphylococcus aureus, Burkholderia species, and non-tuberculous Mycobacteria can afflict patients with chronic respiratory disorders such as cystic fibrosis (CF) and non-CF bronchiectasis.

The benefits of inhaled antibiotics include the ability to deliver large concentrations of medication at the site of infection without the systemic adverse effects seen with parenteral or oral antibiotic treatments. Over the last few decades, there has been a surge in interest in the creation of inhaled antibiotics to aid in the management of infections, particularly those that are difficult to eradicate or have a high recurrence rate. When compared to systemic therapy, antibiotic delivery by inhalation has significant advantages for treating lower airway infections.

Global Inhaled Antibiotics Market Overview

Chronic respiratory airway infections are treated with inhalation antibiotics. These inhaled antibiotics are thought to be more effective than other routes since they provide a higher concentration of medications to the targeted site, which may contribute to the growth of the Inhaled Antibiotics Market. Rising incidence of respiratory diseases such as asthma, pneumonia, chronic obstructive pulmonary diseases (COPD), and bronchitis is expected to drive the growth of the overall Inhaled Antibiotics Market. Asthma is also a major public health issue that affects millions of people worldwide.

Chronic obstructive pulmonary disease (COPD) is another life-threatening lung illness that causes premature death and high mortality rates. Chronic bronchitis and emphysema are both symptoms of Chronic Obstructive Pulmonary Disease (COPD). Moreover, the increasing research and development activities for the development of novel products are also anticipated to boost the Inhaled Antibiotics Market growth. Inhaled antibiotics have long been used to treat pulmonary infections in cystic fibrosis patients, and the pulmonary route is also being explored for other infectious disorders such as tuberculosis especially, with multidrug-resistant and extensively drug-resistant patients.

Whereas side effects associated with drug inhalation and the difficulty of a single effective inhaler device that can treat many disease conditions may hamper the growth of the Inhaled Antibiotics Market. Additionally, the insufficient supply of raw materials such as APIs for antibiotics manufacturing because of irregularities in the transportation facility will affect the global distribution channel of the Inhaled Antibiotics Market.

Global Inhaled Antibiotics Market Segmentation Analysis

The Global Inhaled Antibiotics Market is Segmented into Product Type, Application, Distribution Channel, And Geography.

Inhaled Antibiotics Market, By Product Type

Aerosol/Metered Dose Inhaler
Dry Powder Formulation
Spray
Others

Based on Product Type, the market is bifurcated into Aerosol/Metered Dose Inhaler, Dry Powder Formulation, Spray, and others. The Metered Dose Inhaler segment accounted for the largest share and is anticipated to maintain its lead over the forecast period. This is attributed to its common use in the asthma and chronic obstructive pulmonary disease (COPD) drug delivery devices market.

Inhaled Antibiotics Market, By Application

Pneumonia
Asthma
Bronchitis
Others

Based on Application, the market is bifurcated into Pneumonia, Asthma, Bronchitis, and Others. The asthma segment accounts for the largest share because of genetics or environmental factors such as microbial exposure, passive smoking, and air pollution, the illness burden is increasing in both adults and children, boosting the demand for asthma treatment, which is expected to contribute to the segment's growth.

Inhaled Antibiotics Market, By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Based on Distribution Channel, the market is bifurcated into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The largest market segment is held by retail pharmacies owing to an increase in the popularity of online pharmacies for obtaining prescription pharmaceuticals and customers' consistent use of this distribution channel and due to an increase in the number of treatments administered through them and an increase in the number of retail pharmacies in emerging countries.

Inhaled Antibiotics Market, By Geography

North America
Europe
Asia Pacific
Rest of the world
On the basis of Geography, the Global Inhaled Antibiotics Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America accounts for the largest growing segment due to an increase in the incidence of targeted diseases, an increase in the number of FDA approvals, and several product launches in the United States. Furthermore, the region's market is being driven by an increase in awareness about disease management, including prevention, diagnosis, and treatment, and an increased emphasis on respiratory illness care to improve the market in the region.

Key Players

The "Global Inhaled Antibiotics Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as Gilead Sciences, Aradigm, Lupin Ltd., Polyphor, Insmed Incorporated, Pharmaero, Savara Pharmaceuticals, Joincare Pharmaceutical Group, Pharmaxis Ltd., Raptor Pharmaceutical Corp., Teva Canada Limited, Altan Pharmaceuticals.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

1 INTRODUCTION OF GLOBAL INHALED ANTIBIOTICS MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL INHALED ANTIBIOTICS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL INHALED ANTIBIOTICS MARKET, BY PRODUCT TYPE

5.1 Overview
5.2 Aerosol/Metered Dose Inhaler
5.3 Dry Powder Formulation
5.4 Spray
5.5 Others

6 GLOBAL INHALED ANTIBIOTICS MARKET, BY APPLICATION

6.1 Overview
6.2 Pneumonia
6.3 Asthma
6.4 Bronchitis
6.5 Others

7 GLOBAL INHALED ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL

7.1 Overview
7.2 Hospital Pharmacies
7.3 Retail Pharmacies
7.4 Online Pharmacies

8 GLOBAL INHALED ANTIBIOTICS MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East And Africa

9 GLOBAL INHALED ANTIBIOTICS MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 Gilead Sciences
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Aradigm
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Lupin Ltd.
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Polyphor
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Insmed Incorporated
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Pharmaero
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Savara Pharmaceuticals
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Joincare Pharmaceutical Group
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Pharmaxis Ltd.
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 Raptor Pharmaceutical Corp.
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments
10.11Teva Canada Limited.
- 10.11.1 Overview
- 10.11.2 Financial Performance
- 10.11.3 Product Outlook
- 10.11.4 Key Developments
10.12 Altan Pharmaceuticals.
- 10.12.1 Overview
- 10.12.2 Financial Performance
- 10.12.3 Product Outlook
- 10.12.4 Key Developments